Arrowstreet Capital’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$151M Buy
1,890,859
+1,462,238
+341% +$121M 0.08% 233
2025
Q4
$36.5M Buy
428,621
+146,651
+52% +$12M 0.02% 563
2025
Q3
$21.9M Buy
281,970
+128,096
+83% +$10M 0.01% 699
2025
Q2
$12M Sell
153,874
-112,182
-42% -$8.37M 0.01% 846
2025
Q1
$19.3M Buy
266,056
+220,068
+479% +$15.8M 0.02% 604
2024
Q4
$3.4M Sell
45,988
-43,796
-49% -$3.07M ﹤0.01% 1125
2024
Q3
$5.92M Sell
89,784
-135,236
-60% -$9.83M 0.01% 916
2024
Q2
$20.8M Sell
225,020
-631,986
-74% -$56M 0.02% 470
2024
Q1
$81.9M Sell
857,006
-204,778
-19% -$17.2M 0.08% 225
2023
Q4
$81M Sell
1,061,784
-389,815
-27% -$27.1M 0.08% 200
2023
Q3
$101M Sell
1,451,599
-652,500
-31% -$52.4M 0.12% 156
2023
Q2
$198M Sell
2,104,099
-4,274
-0.2% -$371K 0.24% 101
2023
Q1
$174M Sell
2,108,373
-620,906
-23% -$48.8M 0.23% 118
2022
Q4
$204M Buy
2,729,279
+298,351
+12% +$23M 0.28% 101
2022
Q3
$201M Sell
2,430,928
-365,613
-13% -$35.2M 0.3% 96
2022
Q2
$266M Sell
2,796,541
-515,592
-16% -$53.4M 0.38% 65
2022
Q1
$390M Buy
3,312,133
+51,140
+2% +$5.74M 0.49% 49
2021
Q4
$422M Buy
3,260,993
+708,921
+28% +$82.7M 0.52% 42
2021
Q3
$289M Buy
2,552,072
+1,074,538
+73% +$123M 0.36% 55
2021
Q2
$153M Buy
1,477,534
+512,265
+53% +$48.3M 0.19% 116
2021
Q1
$80.7M Buy
965,269
+941,850
+4,022% +$79.6M 0.11% 189
2020
Q4
$2.14M Sell
23,419
-242,661
-91% -$20.1M ﹤0.01% 1571
2020
Q3
$21.2M Sell
266,080
-1,572,792
-86% -$123M 0.03% 535
2020
Q2
$127M Sell
1,838,872
-632,678
-26% -$45M 0.23% 82
2020
Q1
$155M Buy
2,471,550
+834,342
+51% +$60.2M 0.44% 38
2019
Q4
$127M Buy
+1,637,208
New +$128M 0.3% 66
2019
Q3
Sell
-70,779
Closed -$4.36M 1584
2019
Q2
$4.36M Sell
70,779
-286,161
-80% -$17.3M 0.01% 680
2019
Q1
$22.8M Buy
356,940
+278,025
+352% +$15.9M 0.05% 328
2018
Q4
$4.03M Sell
78,915
-1,415,433
-95% -$71.6M 0.01% 625
2018
Q3
$86.7M Buy
1,494,348
+199,767
+15% +$9.77M 0.2% 120
2018
Q2
$62.8M Buy
1,294,581
+321,867
+33% +$15M 0.15% 151
2018
Q1
$45.2M Buy
972,714
+630,318
+184% +$27.4M 0.1% 200
2017
Q4
$12.9M Sell
342,396
-1,403,730
-80% -$51.5M 0.03% 400
2017
Q3
$63.6M Sell
1,746,126
-694,044
-28% -$26.5M 0.17% 134
2017
Q2
$96.2M Buy
2,440,170
+387,513
+19% +$14.1M 0.29% 97
2017
Q1
$64.4M Buy
+2,052,657
New +$64.3M 0.24% 111
2016
Q4
Sell
-5,791,794
Closed -$233M 1904
2016
Q3
$233M Buy
5,791,794
+118,080
+2% +$4.45M 0.76% 23
2016
Q2
$189M Buy
5,673,714
+2,984,991
+111% +$102M 0.62% 31
2016
Q1
$79.1M Buy
2,688,723
+2,426,091
+924% +$66.9M 0.33% 69
2015
Q4
$6.91M Sell
262,632
-1,967,238
-88% -$51.1M 0.03% 454
2015
Q3
$52.8M Sell
2,229,870
-1,279,218
-36% -$30.9M 0.25% 91
2015
Q2
$83.3M Buy
3,509,088
+651,288
+23% +$14.7M 0.47% 56
2015
Q1
$67.9M Buy
2,857,800
+2,298,528
+411% +$51.6M 0.42% 61
2014
Q4
$11.9M Buy
559,272
+445,266
+391% +$8.95M 0.07% 279
2014
Q3
$1.94M Buy
+114,006
New +$1.8M 0.01% 593
2014
Q2
Sell
-349,224
Closed -$4.32M 1032
2014
Q1
$4.32M Buy
+349,224
New +$4.03M 0.03% 468
2013
Q4
Sell
-293,406
Closed -$3.4M 1192
2013
Q3
$3.4M Sell
293,406
-770,220
-72% -$9.01M 0.02% 446
2013
Q2
$11.9M Buy
+1,063,626
New +$12.6M 0.09% 200

Other funds holding EW

Arrowstreet Capital's EW Position: Q1 2026 in Review

Arrowstreet Capital increased its Edwards Lifesciences (EW) stake by 341% in Q1 2026, buying an estimated $121M and bringing the position to 1,890,859 shares worth $151M. The position accounts for 0.08% of the portfolio, ranked #233.

Arrowstreet Capital first reported a position in EW in Q2 2013 and has held it in 48 quarters since. The position peaked at $422M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Arrowstreet Capital held 1,890,859 shares of Edwards Lifesciences worth $151M as of Q1 2026.
  • Arrowstreet Capital bought 1,462,238 Edwards Lifesciences shares in Q1 2026, an estimated $121M.
  • Edwards Lifesciences made up 0.08% of Arrowstreet Capital's portfolio in Q1 2026, its #233 holding.
  • Arrowstreet Capital first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 48 quarters since.
  • Arrowstreet Capital's Edwards Lifesciences position peaked at $422M in Q4 2021.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.